Clinical diagnosis and management of perihilar cholangiocarcinoma
Joachim Mertens – 1 April 2014 – Watch a video presentation of this article
Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment
M. Valerie Lin, Raymond Chung – 1 April 2014 – Watch a video presentation of this article
Comparison of the tolerance of hepatic ischemia/reperfusion injury in living donors: Macrosteatosis versus microsteatosis
Sangbin Han, Gaabsoo Kim, Suk‐Koo Lee, Choon Hyuck David Kwon, Misook Gwak, Sanghoon Lee, Sangyun Ha, Cheol‐Keun Park, Justin Sangwook Ko, Jaewon Joh – 31 March 2014 – A safe use of intermittent hepatic inflow occlusion (IHIO) has been reported for living donor hepatectomy. However, it remains unclear whether the maneuver is safe in steatotic donors. In addition, the respective importance of macrosteatosis (MaS) and microsteatosis (MiS) is an important issue. Thus, we compared MiS and MaS with respect to the tolerance of hepatic ischemia/reperfusion (IR) injury induced by IHIO.
Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation
Marcus Robertson, Avik Majumdar, Kent Garrett, Greg Rumler, Paul Gow, Adam Testro – 31 March 2014
Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation
Marcus Robertson, Avik Majumdar, Kent Garrett, Greg Rumler, Paul Gow, Adam Testro – 31 March 2014
Inhibition of microRNA‐24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia
Raymond Ng, Heng Wu, Hong Xiao, Xin Chen, Holger Willenbring, Clifford J. Steer, Guisheng Song – 28 March 2014 – The incidence of nonalcoholic fatty liver disease (NAFLD) and hyperlipidemia, with their associated risks of endstage liver and cardiovascular diseases, is increasing rapidly due to the prevalence of obesity. Although the mechanisms of NAFLD have been studied extensively, the underlying pathogenesis and the role of microRNAs in this process remain relatively unclear.
A chronic disease management model for chronic liver failure
Alan J. Wigg, Mohamed A. Chinnaratha, Rachel Wundke, Michael L. Volk – 28 March 2014
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals
Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi – 28 March 2014 – Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals
Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi – 28 March 2014 – Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.
A chronic disease management model for chronic liver failure
Alan J. Wigg, Mohamed A. Chinnaratha, Rachel Wundke, Michael L. Volk – 28 March 2014